Pages that link to "Q33268017"
Jump to navigation
Jump to search
The following pages link to Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura (Q33268017):
Displaying 50 items.
- TPO receptor agonist for chronic idiopathic thrombocytopenic purpura (Q24235481) (← links)
- CD20 deficiency in humans results in impaired T cell-independent antibody responses (Q24653638) (← links)
- Advances in Diagnosis and Treatments for Immune Thrombocytopenia (Q26738630) (← links)
- Current Management of Primary Immune Thrombocytopenia (Q26779408) (← links)
- Immune thrombocytopenia (Q26830918) (← links)
- Contemporary management of primary immune thrombocytopenia in adults (Q26853680) (← links)
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia (Q28305486) (← links)
- Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach (Q28481264) (← links)
- Nanocarriers as an emerging platform for cancer therapy (Q29616699) (← links)
- Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab (Q31150752) (← links)
- Treatment of chronic immune thrombocytopenic purpura: the patients' perspective (Q33374397) (← links)
- Late spontaneous remissions in severe adult autoimmune thrombocytopenia (Q33375260) (← links)
- Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab (Q33375841) (← links)
- Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century (Q33376380) (← links)
- Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis (Q33376705) (← links)
- The potential utility of B cell-directed biologic therapy in autoimmune diseases (Q33377109) (← links)
- New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review (Q33377221) (← links)
- New insights and therapeutics for immune-mediated thrombocytopenia (Q33377901) (← links)
- First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat (Q33378373) (← links)
- Emerging strategies to treat chronic immune thrombocytopenic purpura (Q33378375) (← links)
- Rituximab in the treatment of autoimmune haematological disorders (Q33378854) (← links)
- Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura (Q33379498) (← links)
- Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results (Q33379777) (← links)
- Refractory immune thrombocytopenic purpura: current strategies for investigation and management (Q33380052) (← links)
- Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development (Q33380175) (← links)
- Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura (Q33381337) (← links)
- Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response (Q33382172) (← links)
- Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments (Q33382410) (← links)
- New options after first-line therapy for chronic immune thrombocytopenic purpura (Q33382751) (← links)
- Immune thrombocytopenic purpura: the treatment paradigm (Q33383187) (← links)
- A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus (Q33383190) (← links)
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial (Q33383374) (← links)
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project (Q33383576) (← links)
- Romiplostim: a novel thrombopoiesis-stimulating agent (Q33384183) (← links)
- Immune thrombocytopenic purpura: pathophysiology and treatment (Q33384324) (← links)
- Two-stage design of clinical trials involving recurrent events (Q33385266) (← links)
- Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders (Q33385389) (← links)
- Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report (Q33385546) (← links)
- Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura (Q33385964) (← links)
- Treatment of immune thrombocytopenic purpura: focus on eltrombopag (Q33385976) (← links)
- Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review (Q33386023) (← links)
- Diagnostic and therapeutic management of idiopathic thrombopenic purpura (Q33386868) (← links)
- Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital (Q33387641) (← links)
- Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies (Q33388078) (← links)
- Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia (Q33389001) (← links)
- Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia (Q33389211) (← links)
- The long-term impact of rituximab for childhood immune thrombocytopenia (Q33389323) (← links)
- Use of rituximab in the antiphospholipid syndrome (Q33389337) (← links)
- Low-dose rituximab in adult patients with primary immune thrombocytopenia (Q33390115) (← links)
- Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia (Q33390384) (← links)